Skip to content
15% off your first order15% off your first order

Tesamorelin 20 mg vial

Visceral fat research

Investigated for GHRH signaling and body composition.

$269.00CAD· $13.45/mg
Strength. Which size?
1
  • Ships from Canada in 1–2 business days
  • Free shipping over $120
  • Place your order, then send the e-Transfer. We pack it as soon as it arrives.

For research use only. Not for human consumption.

Complete your setup

Needles and wipes are free. Water is $19.

Compare. Side by side, from the research.

About Tesamorelin

Tesamorelin is a stabilized growth-hormone-releasing hormone analog. Research examines its role in endogenous GHRH signaling and its association with visceral adipose tissue.

How it works

Stabilized Analog
Studied as a modified releasing-hormone analog engineered for greater stability in research settings.
Body Composition
Explored in research on visceral adipose tissue and associated metabolic markers.
Read the full research

What you need

  • Bacteriostatic Water
  • Needles
  • Alcohol Wipes
  • A protocol guide comes with every order

Shipping & payment

  • Packed and dispatched within 1–2 business days
  • Delivered across Canada in 2–5 business days, tracked
  • Temperature-controlled packaging where the product needs it
  • Free shipping on orders over $120
  • Prices in CAD · pay by Interac e-Transfer
Format
Lyophilised powder in a sealed vial
Strength
20 mg per vial
Storage
Refrigerate, away from light. Once reconstituted, keep refrigerated and use within the window on the insert.
Reconstitution
Bacteriostatic water. The calculator shows the concentration for any volume.
Route in research
Subcutaneous
Target
GHRH-R
SKU
TSM20

Handling

  1. 1ReconstituteAdd bacteriostatic water down the side of the vial. Swirl, never shake. Agitation damages the peptide chain.
  2. 2StoreRefrigerate at 2–8°C once mixed. Reconstituted peptide is stable for the window given in your protocol guide.
  3. 3Measure with the calculator Use an insulin syringe at the units your protocol specifies. Rotate sites and log what you take.
Purity
High-performance liquid chromatography (HPLC), by an independent laboratory
Identity
Mass spectrometry, on the same batch
How often
Every batch
COA
The certificate of analysis is matched to the lot code printed on your vial
Evidence
Late clinical

Check your lot

Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.

Late clinicalPublished reviews describe human clinical research on tesamorelin as a growth hormone-releasing factor analogue, particularly in HIV-associated lipodystrophy.

What research examines

  • Visceral adipose tissue in HIV-associated lipodystrophy
  • Endogenous GHRH receptor signaling and pituitary action
  • Downstream metabolic markers linked to body composition
  • Muscle preservation within body-composition research
  • Peptide use in sports medicine and musculoskeletal contexts

Reported in studies

  • Adverse event profiles are covered in clinical reviews but are not summarized here
  • Human safety data for research-grade material outside clinical trials are limited
  • Safety of approved and unapproved peptides in athletic settings has been reviewed as an open question
Read the full research page· 5 cited studies

Published research protocols

1 mg, daily, evening, pre-sleep

Research protocols have used 500–2,000 mcg per administration, once daily (pre-sleep), in 8-week blocks with 4 weeks off.

For research use only. These figures summarize published research protocols. They are not instructions or medical advice.

Measure with the calculator

CoreX AI

Ask about Tesamorelin

Plain answers, from the basics to the studies.

Research information, not medical advice.

Often researched with Tesamorelin

Researched for weight & body composition.

Shop Weight & body composition

FAQ

Questions, answered

  • Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). It has been modified to be more stable than the native hormone while retaining activity at the GHRH receptor. Published reviews describe it as a human growth hormone releasing factor analogue, and research has examined its role in endogenous GHRH signaling and its association with visceral adipose tissue. It is supplied by CoreX for laboratory research use only.

  • Research describes tesamorelin as acting on the GHRH receptor (GHRH-R) at the pituitary, the same target as the native releasing hormone. Its structural modifications are intended to give it greater stability than endogenous GHRH. Studies have focused on this pituitary action and on downstream metabolic signaling, including effects associated with growth hormone release and changes in body composition markers such as visceral fat.

  • The best-documented research area is HIV-associated lipodystrophy, where reviews describe tesamorelin's study in relation to visceral adipose tissue. Research has also examined associated metabolic markers and the broader question of muscle preservation within body-composition work. More recent reviews in orthopaedic and sports medicine literature discuss tesamorelin alongside other injectable peptides, while noting that evidence in those settings is more limited than in its primary clinical research area.

  • Clinical reviews of tesamorelin discuss its adverse event profile from human studies, but those findings are not summarized on this page. Human safety data outside controlled clinical research, including for research-grade material, are limited. Reviews of approved and unapproved peptide therapies in musculoskeletal and athletic contexts have highlighted safety and efficacy as areas where further evidence is needed. Findings from specific trial populations should not be generalized to other settings.

  • Research protocols have used 500 to 2,000 mcg per administration, given once daily before sleep by the subcutaneous route, in 8-week blocks followed by 4 weeks off. These figures describe what research protocols have used and are not a recommendation. Each CoreX order ships with a protocol guide for laboratory reference, and the compound is sold for research use only.

Vial · Pen

Dual-agonist weight research

Tirzepatide · 2 sizes

$139/ 30 mg vial

Vial · Pen

Triple-agonist weight research

GLP-3R · 4 sizes

$119/ 10 mg vial